目的 探討地奧心血康軟膠囊聯(lián)合美托洛爾治療不穩(wěn)定型心絞痛的臨床療效。方法 選取2022年3月-2023年3月亳州市人民醫(yī)院收治的106例不穩(wěn)定型心絞痛患者，按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各53例。對(duì)照組早飯前口服琥珀酸美托洛爾緩釋片，1片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上飯后口服地奧心血康軟膠囊，2粒/次，3次/d。兩組療程均為2周。觀察兩組的臨床療效，比較治療前后兩組心絞痛發(fā)作情況、心肌缺血時(shí)間、醫(yī)學(xué)結(jié)局研究簡(jiǎn)短量表-8（SF-8）和西雅圖心絞痛量表（SAQ）評(píng)分、外周血中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）及血清超敏C反應(yīng)蛋白（hs-CRP）、心肌肌鈣蛋白I （cTnI）、N末端B型利鈉肽原（NT-proBNP）水平。結(jié)果 治療后，治療組總有效率是92.45%，顯著高于對(duì)照組的77.36%（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)、硝酸甘油用量均顯著降低，持續(xù)時(shí)間均顯著縮短（P<0.05）；治療組心絞痛發(fā)作情況改善優(yōu)于對(duì)照組（P<0.05）。治療后，兩組心肌缺血時(shí)間均顯著縮短（P<0.05），SF-8、SAQ評(píng)分均顯著增加（P<0.05），以治療組改善更顯著（P<0.05）。治療后，兩組外周血NLR和血清hs-CRP、cTnI、NT-proBNP水平均顯著下降（P<0.05）；且以治療組顯著更低（P<0.05）。結(jié)論 地奧心血康軟膠囊聯(lián)合美托洛爾治療不穩(wěn)定型心絞痛有較好的臨床療效，能有效控制心絞痛發(fā)作、緩解心肌缺血狀態(tài)，減輕機(jī)體炎癥損傷和心肌損害，患者耐受性較好，且利于病情控制及生活質(zhì)量的改善，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Di'ao Xinxuekang Soft Capsules combined with metoprolol in treatment of unstable angina pectoris. Methods A total of 106 patients with unstable angina pectoris treated in Bozhou People's Hospital from March 2022 to March 2023 were selected and divided into control group and treatment group according to random number table method, with 53 cases in each group. Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets before breakfast, 1 tablet/time, once daily. Patients in the treatment group were po administered with Di'ao Xinxuekang Soft Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the angina attack, myocardial ischemia time, medical outcome study short scale 8 (SF-8) and Seattle Angina Scale (SAQ) scores, peripheral blood neutrophil lymphocyte ratio (NLR), serum high-sensitivity C-reactive protein (hs CRP), myocardial Troponin I (cTnI), and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 92.45%, which was significantly higher than that of the control group (77.36%, P < 0.05). After treatment, the frequency of angina pectoris attacks and the dosage of nitroglycerin were significantly decreased in both groups, and the duration was significantly shortened (P < 0.05). The improvement of angina pectoris in the treatment group was better than that in the control group (P< 0.05). After treatment, myocardial ischemia time in both groups was significantly shortened (P < 0.05), and SF-8 and SAQ scores were significantly increased (P < 0.05). The improvement was more significant in the treatment group (P < 0.05). After treatment, the levels of peripheral blood NLR, serum hs-CRP, cTnI and NT-proBNP in both groups were significantly decreased (P < 0.05). It was significantly lower in the treatment group (P < 0.05). Conclusion Di'ao Xinxuekang Soft Capsules combined with metoprolol has good clinical effect in treatment of unstable angina pectoris, can effectively control the attack of angina pectoris, relieve myocardial ischemia, reduce inflammation and myocardial damage, and patients have good tolerance, and it is conducive to disease control and improvement of life quality, which is worthy of clinical promotion and application.

R972

安徽省重點(diǎn)研究與開(kāi)發(fā)計(jì)劃項(xiàng)目（2022e07020066）